Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation

Padalino, Gilda, El-Sakkary, Nelly, Liu, Lawrence J., Liu, Chenxi, Harte, Danielle S.G., Barnes, Rachel E., Sayers, Edward, Forde-Thomas, Josephine, Whiteland, Helen, Bassetto, Marcella, Ferla, Salvatore, Johnson, George, Jones, Arwyn T., Caffrey, Conor R., Chalmers, Iain, Brancale, Andrea and Hoffmann, Karl F. 2021. Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation. European Journal of Medicinal Chemistry 226 , 113823. 10.1016/j.ejmech.2021.113823 Item availability restricted.

PDF - Accepted Post-Print Version Restricted to Repository staff only until 10 September 2022 due to copyright restrictions. Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (633kB)

Abstract

Schistosomiasis is a neglected disease of poverty that is caused by infection with blood fluke species contained within the genus Schistosoma. For the last 40 years, control of schistosomiasis in endemic regions has predominantly been facilitated by administration of a single drug, praziquantel. Due to limitations in this mono-chemotherapeutic approach for sustaining schistosomiasis control into the future, alternative anti-schistosomal compounds are increasingly being sought by the drug discovery community. Herein, we describe a multi-pronged, integrated strategy that led to the identification and further exploration of the quinoxaline core as a promising anti-schistosomal scaffold.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	Elsevier
ISSN:	0223-5234
Date of First Compliant Deposit:	22 September 2021
Date of Acceptance:	27 August 2021
Last Modified:	11 Oct 2021 16:56
URI:	https://orca.cardiff.ac.uk/id/eprint/144330

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item